Brepocitinib (PF-06700841)

Cat. No.: OB0225WX-2780

Appearance: Solid

Purity: ≥98%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Brepocitinib is a dual-target inhibitor of Tyk2 and Jak1 (IC50: 23 nM and 17 nM, respectively) with a favorable selectivity profile against JAK2 and JAK3.

Synonym: PF-841; 1883299-62-4; Brepocitinib; PF-06700841; PF-06700841 free base; [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; [(1S)-2,2-difluorocyclopropyl]-[(1S,5R)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; PF06700841; [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; Methanone, ((1S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-; PF-841; ((1S)-2,2-difluorocyclopropyl)-((1S,5R)-3-(2-((1-methylpyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo(3.2.1)octan-8-yl)methanone; 4-((1R,5S)-8-((1S)-2,2-difluorocyclopropanecarbonyl)-3,8-diazabicyclo(3.2.1)octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine; 4-[(1R,5S)-8-[(1S)-2,2-difluorocyclopropanecarbonyl]-3,8-diazabicyclo[3.2.1]octan-3-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine

CAS No.: 1883299-62-4

Compound CID: 118878093

Formula: C₁₈H₂₁F₂N₇

Formula Weight: 389.4

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Brepocitinib is applied in immunology research as a potent dual inhibitor of TYK2 and JAK1 to study the modulation of multiple cytokine pathways involved in the pathogenesis of psoriasis and other inflammatory diseases.